AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Futura Medical plc
Video analysis: FAMDF
All videosNo video analysis for this stock yet. Request one from our team.
News: FAMDF
Futura Medical upsizes retail offer after strong investor demand
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its...
Futura Medical upsizes retail offer after strong investor demand
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its retail share offer after strong demand from investors. The retail offer closed on Friday, having attracted applications well beyond the company's original target.
Dow closes with strong gains as rate fears take a back seat
4:25pm: Rate fears fade Wall Street ended Thursday sharply higher, with the Dow and S&P 500 posting their best daily performances in about a month as easing...
Bitcoin price recovery narrows odds on higher 2026 targets, prediction market data shows
Bitcoin was trading at $77,121 on Thursday, having clawed back much of its summer losses in a sharp August rally. The cryptocurrency gained roughly 24%...
Futura Medical launches formal sale process alongside £1.6m placing
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets. The move comes alongside a placing and subscription to raise approximately £1.6 million, which should fund it through to the conclusion of negotiations.
Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market Performance Group as its new US commercial partner from 1 September, replacing Haleon after a two-month transition.
Futura Medical gets greenlight for stronger product "Eroxon Intense"
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European...
Futura Medical gets greenlight for stronger product "Eroxon Intense"
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European Economic Area and UK, widening the group's flagship consumer-health franchise. The clearance follows the completion of design, validation and pre-market regulatory work under Futura's existing European CE certification and UKCA approval.
